TransMedics reiterates 2026 revenue outlook of $737 million-$757 million
TMDX•2026 revenue guidance reiterated
TransMedics reiterated full-year 2026 revenue guidance of $737 million to $757 million.
The outlook implies about 22% to 25% year-over-year growth.
The forecast excludes any revenue contribution from its recent strategic investment in PAD Aviation Service GmbH.
Guidance is set to be revisited with third-quarter 2026 results.
